Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis

Table 2 Meta regression

	MSI status	Monotherapy or combination therapy	PD-1 or PD-L1 inhibitors	Nivolumab, pembrolizumab or others (Nivolumab)	Nivolumab, pembrolizumab or others (pembrolizumab)
ORR	0*	0.576	0.086	0.079	0.017*
DCR	0.012*	0.04*	0.688	0.062	0.964
CR	0.001*	0.566	0.017*	0.821	0.406
PR	0.001*	0.567	0.076	0.044*	0.009*
SD	0.835	0.284	0.335*	0.084	0.018*
PD	0.004*	0.972	0.051	0.1	0.549
AEs	0.607	0.259	0.036*	0.44	0.867
SAE	0.51	0.151	0.058	0.958	0.606
PFS	0.034*	0.75	0.908	0.031*	0.122
OS	0.029*	0.962	0.025*	0.188	0.188

P value < 0.05 means significant statistical differences. ORR objective response rate, DCR disease control rate, CR complete response rate, PR partial response rate, SD stable disease rate, PD progression disease rate, AEs adverse events, SAEs severe adverse events, PFS 1-year progression-free survival rate, OS 1-year overall survival rate (OS)

ISSN: 1477-7819